Evidence map›Paper›PMID 34242377›Full record

ArticlePloS one2021

Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.

Mioljub Ristić, Biljana Milosavljević, Slobodanka Vapa, Miloš Marković, Vladimir Petrović

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Mioljub RistićDepartment of Epidemiology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.ORCID 0000-0002-6923-189X
Biljana MilosavljevićInstitute of Public Health of Vojvodina, Novi Sad, Serbia.
Slobodanka VapaInstitute of Public Health of Vojvodina, Novi Sad, Serbia.
Miloš MarkovićDepartment of Immunology, Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, Belgrade, Serbia.
Vladimir PetrovićDepartment of Epidemiology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Institute of Public Health of Vojvodina · RSUniversity of Novi Sad · RSUniversity of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMonitoring changes of seroprevalence over time is important at the beginning and during of COVID-19 outbreak to anticipate its dynamics and plan an adequate public health response.

methodsWe conducted a repeated cross-sectional investigation among asymptomatic outpatient subjects and covered 0.1% of total population of Northern Serbia (Autonomous Province of Vojvodina). Each participant was tested for anti-SARS-CoV-2 antibodies using an immunochromatographic qualitative test (point-of-care rapid test). In the last round of survey IgG antibodies targeting the S1 subunit of the spike protein and the nucleocapsid protein of SARS-CoV-2 virus were assessed.

resultsDuring the four rounds of survey (between the end of April and the end of September), anti-SARS-CoV-2 seropositivities based on immunochromatographic test results were 2.60% (95% CI 1.80-3.63), 3.93% (95% CI 2.85-5.28), 6.11% (95% CI 4.72-7.77) and 14.60% (95% 12.51-16.89), respectively. After adjusting with results obtained from the Line immunoassay test, the estimated overall seroprevalence increased to 16.67% (95% CI 14.45-19.08) corresponding to 322,033 infections in total by the end of September 2020 in Vojvodina's population. Throughout the course of the study, for every RT-PCR confirmed case of COVID-19, there were 39-87 additional infections in Vojvodina. No significant difference (p>0.05) in SARS-CoV-2 seropositivity regarding gender and between age subgroups was observed over the course of the survey.

conclusionsThe population prevalence of SARS-CoV-2 antibodies implies much more widespread infection in Vojvodina than indicated by the number of confirmed cases. However, our results suggest that the population of Vojvodina has not reached a desirable level of protection from SARS-CoV-2 virus by the end of September 2020.

Indexed as

COVID-19COVID-19 Nucleic Acid TestingAdolescentAdultAgedAntibodies, ViralChildChild, PreschoolCross-Sectional StudiesFemaleHumansImmunoglobulin GImmunoglobulin MInfantInfant, NewbornMaleAntibodies, ViralImmunoglobulin GImmunoglobulin M

Identifiers

PMID34242377
PMCPMC8270141
OpenAlexW3178310059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.